Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3696745 | 0.99 | HTR6 (0.37) | HTR6HRH3KCNH2MEN1KMT2A | |
| SCHEMBL2151647 | 0.87 | HTR6 (0.39) | HTR6HRH3KCNH2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2151722 | 0.86 | HTR6 (0.38) | HTR6HRH3KCNH2MEN1KMT2A | |
| Diethylamine SCHEMBL2151568 | 0.79 | MEN1 (0.33) | HTR6MEN1KMT2ASIGMAR1CHRM5 | |
| SCHEMBL2012120 | 0.77 | L3MBTL3 (0.31) | HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL2012118 | 0.77 | L3MBTL3 (0.31) | HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL2012122 | 0.77 | L3MBTL3 (0.31) | HTR6L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29716176 | 0.76 | L3MBTL3 (0.30) | HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL7392128 | 0.70 | KDM4E (0.34) | KMT2A | |
| SCHEMBL1026396 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909205-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-08-26 | — | — | EP | claimed |
| WO-2014062196-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-24 | — | — | WO | claimed |
| EP-2705049-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-03-12 | — | — | EP | claimed |
| WO-2012151195-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-08 | — | — | WO | claimed |
| EP-2504344-A1 | HEPATITIS C INHIBITOR COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2012-10-03 | — | — | EP | claimed |
| EP-3694512-A1 | METHODS FOR TREATING HCV | Abbvie Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019074507-A1 | METHODS FOR TREATING HCV | ABBVIE INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019046569-A1 | METHODS FOR TREATING HCV | ABBVIE INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019027694-A1 | METHODS FOR TREATING HCV | ABBVIE INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-3313398-A1 | METHODS FOR TREATING HCV | AbbVie Inc. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2017004053-A1 | METHODS FOR TREATING HCV | ABBVIE INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| EP-3099295-A1 | DOSE ADJUSTMENT IN COMBINATION THERAPY OF HEPATITIS C | Abbvie Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2576564-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012151195-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-2504344-A1 | HEPATITIS C INHIBITOR COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2012-10-03 | — | — | EP | disclosed |
| WO-2012092411-A2 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | WO | disclosed |
| WO-2011156337-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | WO | disclosed |
| EP-2340029-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2011063502-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2010030359-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARJMACEUTICALS, INC. (US) | 2010-03-18 | — | — | WO | disclosed |